Summit Therapeutics is trading 5.03% up now at $13.13, with no confirmed company-specific catalyst identified.
- No announcement, filing, earnings release, or analyst action dated August 21, 2026, was identified in available search results.
- The latest material company news was the August 12 China approval of ivonescimab with chemotherapy, predating this move.
- The gain appears to be an unexplained intraday rebound rather than a confirmed company catalyst.